secwatch.observer — SEC 8-K summary
======================================

Issuer:     RayzeBio, Inc. (—)
CIK:        0001825367
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001140361-24-009377
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 5.03, 3.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers Squibb completes acquisition of RayzeBio for $62.50 per share in cash
--------------------------------------------------------------------------------

- Bristol-Myers Squibb acquired RayzeBio at $62.50/share; 53,052,499 shares tendered (~86% of outstanding).
- Merger effective Feb 26, 2024; all outstanding shares converted to right to receive $62.50 cash per share.
- Stock options fully vested and cashed out for excess of $62.50 over exercise price.
- All directors resigned; new directors from Bristol-Myers appointed; executive officers replaced.
- Company to delist from Nasdaq and file Form 15 to terminate SEC reporting obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/ef20022333_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-009377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer